Navigation Links
Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
Date:4/21/2008

Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, the risk that the Company does not achieve the financial and operating results it expects and such other risks as identified in the company's quarterly report on Form 10-K for the period ended December 31, 2007, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate Web site at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, contact:

Trubion Pharmaceuticals Inc.

Jim DeNike

Senior Director, Corporate Communication

(206) 838-0500

jdenike@trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

(617) 576-5788


SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BUFFALO, N.Y. , Dec. 24, 2014 ... been dosed with KX2-361 at Roswell Park Cancer Institute. ... a small molecule drug that has shown potent inhibitory ... lines, including those that are resistant to Temozolomide (T98G), ... malignant glioma. In a well-established brain tumor mouse model, ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... FRANKFORT, Ky., Oct. 7, 2011 The Consumer ... the Kentucky General Assembly to adopt a new ... and abuse, the Meth Offender Registry Block List. ... from purchasing medicines containing pseudoephedrine (PSE) –medicines like ...
... Pharmaceuticals, Inc. (NYSE: WPI ) today confirmed ... an Abbreviated New Drug Application (ANDA) with the U.S. ... Morphine Sulfate and Naltrexone Hydrochloride Extended-release Capsules 30 mg/1.2 ... mg, and 100 mg/4 mg.  Watson,s Morphine Sulfate and ...
Cached Medicine Technology:Consumer Group Advances Alternative to Prescription Mandate 2Consumer Group Advances Alternative to Prescription Mandate 3Watson Confirms EMBEDA(R) Patent Challenge 2Watson Confirms EMBEDA(R) Patent Challenge 3
(Date:12/24/2014)... Dr. Svetlana Gomer, MGS Tewksbury Dental, ... gathered with US Marines on November 14, 2014 for ... the Toys for Tots Literacy Program. This year’s ... books and audio books for the Toys for Tots ... Christmas. It represents another major strike in the battle ...
(Date:12/24/2014)... 2014 The report offers details on ... various market dynamics such as the key trends, the ... wait time for U.S. sports medicine, the impact of ... the challenges faced by the market. , Browse report ... The report also provides an overview of the global ...
(Date:12/24/2014)... Verde Pointe Dental Associates 2014 Ugly Holiday ... years homemade Christmas sweater lit up, but this years overall ... is Tandy Wilson for the second year in a row. ... Kimmerling DDS. "She took pictures of the entire staff and ... , "Every year I enjoy stopping by the dental ...
(Date:12/24/2014)... Dental implants benefit millions of individuals ... They offer the strongest and most secure hold for ... of tooth replacement. They will never slip out of ... for support, and they prevent the jaw from shrinking ... they are not suitable candidates for dental implants because ...
(Date:12/24/2014)... 24, 2014 Attorneys handling talcum powder ... update to their website, the Talcum Powder Ovarian ... talcum powder class action lawsuits and ovarian cancer claims. ... ovarian cancer updates at their website, which serves as ... ovarian cancer claims are not the same as class ...
Breaking Medicine News(10 mins):Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4
... University of Texas, offer some valuable advice on how to ... essential for healthy bones and teeth, and helps prevent osteoporosis ... helps the body produce vitamin D.// Just10 to 15 minutes ... But be warned many factors can reduce sunlight exposure, such ...
... with transplanted hearts from female donors, the proof is the ... at least somewhat by recruiting cells from elsewhere in the ... or dead, they could not be replaced or repaired by ... is found only in men, researchers determined that the female ...
... oxygen therapy at home reduces hospitalisation in those with lung ... the effects of oxygen on 200 patients with smoker's lungs// ... was begun in an outpatient clinic, then continued at home. ... a day, proved to be beneficial. The patients had a ...
... study, a combined scan identifies unstable areas of plaque in ... the future. Fatty deposits, known as plaque, set the scene ... - begins many years before any symptoms occur.// The plaque ... a clot which will then cause a heart attack. ...
... recent study by researchers at the University of Texas, have ... cancer.Omega-3 fatty acids, which are found in fish oil, have ... that the omega-3s block a molecule called protein kinase C ... division. ,In this study, genetically-modified mice, which produce ...
... suggested by researchers to relieve chronic headaches. Botox injections ... not relieved by conventional medication. Botox is shorthand for ... to man. However, it does have some benign uses ... out wrinkles in cosmetic surgery. Now researchers at the ...
Cached Medicine News:
0.5 mm wide x 1.5 mm long. Angled 20 degrees. Octagonal handle....
2 mm wide curved tip. Round handle....
8 mm downcutting Royce blade. Angled shaft. 60 mm from angle to tip....
3 mm disposable Lance blade. Can fit in to the N0521 Storz handle....
Medicine Products: